About MILLENDO THERAPEUTICS
Millendo Therapeutics is focused on developing novel treatments for endocrine diseases. Our mission is to build a leading endocrine company that creates distinct and transformative treatments for a wide range of diseases where there is a significant unmet medical need. We are currently advancing two product candidates: livoletide (AZP-531) and nevanimibe (ATR-101). Livoletide is being developed for Prader-Willi syndrome while nevanimibe is in development for the treatment of two different orphan adrenal diseases: Classic Congenital Adrenal Hyperplasia (CAH) and Endogenous Cushing’s Syndrome (CS).
|
|
|
1-10 employees
View all MILLENDO THERAPEUTICS employees
|
|
Biotechnology Research
|
|
7348459000
|
|
301 N Main St, Ann Arbor, Michigan 48104, US
|
|
2012
|
|
Pharmaceuticals, Endocrinology, Biotech
|
MILLENDO THERAPEUTICS Alternatives
Frequently Asked Questions about MILLENDO THERAPEUTICS
The decision makers in Millendo Therapeutics are Gary Hammer, John Kirk, etc. Click to Find Millendo Therapeutics decision makers emails.
MILLENDO THERAPEUTICS Staff Directory
Search MILLENDO THERAPEUTICS Staff Directory
Find accurate personal emails, work emails and phone numbers for employees
Supercharge your
Prospecting &
Outreach with
ContactOut
Supercharge your Prospecting &
Outreach with ContactOut
Find countless prospects outside of LinkedIn fast
Accelerate prospecting with instant access to 350M professionals from 40M companies with the right contact details.
